Successful Utilization of the GLP-1 Receptor Agonist Semaglutide in Treating the Manifestations of Recalcitrant Celiac Disease
A refractory case of abdominal swelling (pseudoascites) due to celiac disease which did not respond to monotherapy with a gluten-free diet and for which treatment with traditional immunosuppressives was refused is described. Based on reports of the anti-inflammatory actions of the GLP-1 receptor agonist, semaglutide, weekly subcutaneous injections of semaglutide were added to the gluten-free diet with rapid and obvious success. Semaglutide and perhaps other GLP-1 receptor agonists should be considered for use as a largely safe anti-inflammatory drug in other autoimmunopathies and inflammatory states.
Authors
- David S.H. Bell (ORCID: https://orcid.org/0000-0002-3035-6126)
- Terri Jerkins (ORCID: https://orcid.org/0009-0007-5241-3797)
Publication Details
- Journal
- Archives of Clinical and Biomedical Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.26502/acbr.50170480
- Primary Topic
- Celiac Disease Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00